4-[2-(diethoxyphosphoryl)-2-fluorovinyl]-2,2-dimethoxyoxazolidine-3-carboxylic acid tert-butyl ester | 654067-59-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: 4-[2-(diethoxyphosphoryl)-2-fluorovinyl]-2,2-dimethoxyoxazolidine-3-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl (4R)-4-[(E)-2-diethoxyphosphoryl-2-fluoroethenyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
• CAS: 654067-59-1
• 化学式: C₁₆H₂₉FNO₆P
• 分子量: 381.382
• InChiKey: IYEIZYZTPMLBKU-GMCKNXKJSA-N

物化性质

• 沸点：
  449.1±45.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  74.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[2-(diethoxyphosphoryl)-2-fluorovinyl]-2,2-dimethoxyoxazolidine-3-carboxylic acid tert-butyl ester 在 palladium on activated charcoal jones reagent 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 丙酮 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists

  摘要：

  The synthesis of N-arylamide phosphonates and related arylether and arylamine analogues provided potent, subtype-selective agonists and antagonists of the five known sphingosine I-phosphate (SIP) receptors (S1P(1-5)). To this end, the syntheses of phosphoserine mimetics-selectively protected and optically active phosphonoserines-are described. In vitro binding assays showed that the implementation of phosphonates as phosphate mimetics provided compounds with similar receptor binding affinities as compared to their phosphate precursors. meta-substituted arylamide phosphonates were discovered to be antagonists of the S1P(1) and S1P(3) receptors. When administered to mice, an antagonist blocked the lymphopenia evoked by a SIP receptor agonist and caused capillary leakage in both lung and kidney. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.060
• 作为产物：
  描述：

  Boc-L-丝氨酸甲酯 在 sodium tetrahydroborate 、 正丁基锂 、 草酰氯 、 三氟化硼乙醚 、 对甲苯磺酸 、 二甲基亚砜 、 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 、 二氯甲烷 、 丙酮 为溶剂， 反应 6.75h， 生成 4-[2-(diethoxyphosphoryl)-2-fluorovinyl]-2,2-dimethoxyoxazolidine-3-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists

  摘要：

  The synthesis of N-arylamide phosphonates and related arylether and arylamine analogues provided potent, subtype-selective agonists and antagonists of the five known sphingosine I-phosphate (SIP) receptors (S1P(1-5)). To this end, the syntheses of phosphoserine mimetics-selectively protected and optically active phosphonoserines-are described. In vitro binding assays showed that the implementation of phosphonates as phosphate mimetics provided compounds with similar receptor binding affinities as compared to their phosphate precursors. meta-substituted arylamide phosphonates were discovered to be antagonists of the S1P(1) and S1P(3) receptors. When administered to mice, an antagonist blocked the lymphopenia evoked by a SIP receptor agonist and caused capillary leakage in both lung and kidney. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.060

文献信息

• Compounds Active in Sphingosine 1-Phosphate Signaling
  申请人：Lynch R. Kevin

  公开号：US20070219163A1

  公开（公告）日：2007-09-20

  The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure: wherein R 11 is C 5 -C 18 alkyl or C 5 -C 18 alkenyl; Q is C 3 -C 6 optionally substituted cycloalkyl, C 3 -C 6 optionally substituted heterocyclic, C 3 -C 6 optionally substituted aryl C 3 -C 6 optionally substituted heteroaryl or —NH(CO)—; R 3 is H, C 1 -C 4 alkyl, (C 1 -C 4 alkyl)OH or (C 1 -C 4 alkyl)NH 2 ; R 23 is H or C 1 -C 4 alkyl, and R 15 is hydroxy, phosphonate, or wherein X and R 12 is O or S; or a pharmaceutically acceptable salt or tautomer thereof.

  本发明涉及具有S1P受体调节剂活性的S1P类似物，以及使用这些化合物治疗与不适当的S1P受体活性相关的疾病。这些化合物具有以下一般结构：其中R11是C5-C18烷基或C5-C18烯基；Q是C3-C6可选取代的环烷基，C3-C6可选取代的杂环基，C3-C6可选取代的芳基，C3-C6可选取代的杂芳基或—NH（CO）—；R3是H，C1-C4烷基，（C1-C4烷基）OH或（C1-C4烷基）NH2；R23是H或C1-C4烷基，R15是羟基，膦酸酯或其中X和R12是O或S；或其药学上可接受的盐或互变异构体。
• Orally available sphingosine 1-phosphate receptor agonists and antagonists
  申请人：Lynch R. Kevin

  公开号：US20070088002A1

  公开（公告）日：2007-04-19

  The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R 11 is C 5 -C 18 alkyl or C 5 -C 18 alkenyl; Q is selected from the group consisting of C 3 -C 6 optionally substituted cycloalkyl, C 3 -C 6 optionally substituted heterocyclic, C 3 -C 6 optionally substituted aryl C 3 -C 6 optionally substituted heteroaryl and; R 2 is selected from the group consisting of H, C 1 -C 4 alkyl, (C 1 -C 4 alkyl)OH and (C 1 -C 4 alkyl)NH 2 ; R 23 is H or C 1 -C 4 alkyl, and R 15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

  本发明涉及具有S1P受体调节剂活性的S1P类似物，并使用这些化合物治疗与不适当S1P受体活性相关的疾病。这些化合物具有一般结构（I），其中R11为C5-C18烷基或C5-C18烯基；Q选自C3-C6可选取代的环烷基、C3-C6可选取代的杂环、C3-C6可选取代的芳基、C3-C6可选取代的杂芳基；R2选自H、C1-C4烷基、（C1-C4烷基）OH和（C1-C4烷基）NH2；R23为H或C1-C4烷基，R15为磷酸酯或磷酸酯酯或其药学上可接受的盐或互变异构体。
• US7241790B2
  申请人：——

  公开号：US7241790B2

  公开（公告）日：2007-07-10
• US7560477B2
  申请人：——

  公开号：US7560477B2

  公开（公告）日：2009-07-14
• US7638637B2
  申请人：——

  公开号：US7638637B2

  公开（公告）日：2009-12-29